{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:19:58Z","timestamp":1791393598515,"version":"4.3.3"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014252","name":"International Association for Bear Research and Management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016226","name":"Accuray","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102464","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:25:11Z","timestamp":1663673111000},"page":"102464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"110","author":[{"given":"Stefania","family":"Volpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Piperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Maria Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Casbarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Spaggiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Alterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102464_b0005","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 2021; caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.ctrv.2022.102464_b0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2015.90","article-title":"Refining the treatment of NSCLC according to histological and molecular subtypes","volume":"12","author":"Thomas","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0015","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.21037\/tlcr-20-728","article-title":"A narrative review of invasive diagnostics and treatment of early lung cancer","volume":"10","author":"Dziedzic","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102464_b0020","unstructured":"NCCN- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)- Non-Small Cell Lung Cancer. Version 4.2021- March 3, 2021, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.ctrv.2022.102464_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijrobp.2014.05.055","article-title":"Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis","volume":"90","author":"Zheng","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102464_b0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.semradonc.2020.11.003","article-title":"Hypofractionation in Early Stage Non-Small Cell Lung Cancer","volume":"31","author":"Wrona","year":"2021","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1016\/j.ctrv.2022.102464_b0045","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0050","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0055","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.ijrobp.2011.01.038","article-title":"Dose-Response for Stereotactic Body Radiotherapy in Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"81","author":"Olsen","year":"2011","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtho.2019.08.2505","article-title":"Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC","volume":"15","author":"Moreno","year":"2020","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0065","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.ijrobp.2011.04.034","article-title":"Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis","volume":"81","author":"Zhang","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102464_b0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: A systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrclinonc.2017.30","article-title":"Charged-particle therapy in cancer: clinical uses and future perspectives","volume":"14","author":"Durante","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0080","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semradonc.2020.11.004","article-title":"Physics of Particle Beam and Hypofractionated Beam Delivery in NSCLC","volume":"31","author":"Paganetti","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0085","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1470-2045(20)30246-1","article-title":"Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer","volume":"21","author":"Ramella","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0090","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2010.03.012","article-title":"Proton Stereotactic Body Radiation Therapy for Clinically Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer","volume":"80","author":"Register","year":"2011","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijrobp.2018.02.022","article-title":"Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer","volume":"101","author":"Nantavithya","year":"2018","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.radonc.2017.05.007","article-title":"Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis","volume":"123","author":"Chi","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0105","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/cancers13061468","article-title":"Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy","volume":"13","author":"Marcus","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2022.102464_b0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/cancers7010353","article-title":"Proton Radiobiology","volume":"7","author":"Tommasino","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2022.102464_b0115","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/1471-2164-14-372","article-title":"Distinct transcriptome profiles identified in normal human bronchial epithelial cells after exposure to \u03b3-rays and different elemental particles of high Z and energy","volume":"14","author":"Ding","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ctrv.2022.102464_b0120","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.4161\/cbt.7.12.7417","article-title":"Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo","volume":"7","author":"Finnberg","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2022.102464_b0125","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/JTO.0b013e3182a5fdcb","article-title":"Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation","volume":"8","author":"Zhang","year":"2013","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1667\/RR2724.1","article-title":"Proton Irradiation Suppresses Angiogenic Genes and Impairs Cell Invasion and Tumor Growth","volume":"178","author":"Girdhani","year":"2012","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctrv.2022.102464_b0135","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1038\/srep13961","article-title":"Proton beam radiation induces DNA damage and cell apoptosis in glioma stem cells through reactive oxygen species","volume":"5","author":"Alan Mitteer","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2022.102464_b0140","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1667\/RR14951.1","article-title":"In Vitro Radiobiological Advantages of Hypofractionation Compared with Conventional Fractionation: Early-Passage NSCLC Cells are Less Aggressive after Hypofractionation","volume":"190","author":"Zhang","year":"2018","journal-title":"Radiat Res"},{"key":"10.1016\/j.ctrv.2022.102464_b0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2022.102464_b0150","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.cllc.2013.11.002","article-title":"Outcomes and Prognostic Factors for Recurrence After High-Dose Proton Beam Therapy for Centrally and Peripherally Located Stage I Non\u2013Small-Cell Lung Cancer","volume":"15","author":"Kanemoto","year":"2014","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.ctrv.2022.102464_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00013.1","article-title":"Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study","volume":"7","author":"Kharod","year":"2020","journal-title":"Int J Particle Therapy"},{"key":"10.1016\/j.ctrv.2022.102464_b0160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2019.07.008","article-title":"Estimation of the \u03b1\/\u03b2 ratio of non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"142","author":"Klement","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The Combination of Estimates from Different Experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.ctrv.2022.102464_b0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2022.102464_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ctrv.2022.102464_b0180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00066-016-0985-9","article-title":"Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas: Ablative dose PBT for NSCLC","volume":"192","author":"Lee","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ctrv.2022.102464_b0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(02)04416-4","article-title":"Clinical evaluation of proton radiotherapy for non\u2013small-cell lung cancer","volume":"56","author":"Shioyama","year":"2003","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0190","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ijrobp.2006.12.063","article-title":"Hypofractionated High-Dose Proton Beam Therapy for Stage I Non\u2013Small-Cell Lung Cancer: Preliminary Results of A Phase I\/II Clinical Study","volume":"68","author":"Hata","year":"2007","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0195","first-page":"NA-NA","article-title":"High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer","author":"Iwata","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102464_b0200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/0284186X.2014.948060","article-title":"High-dose proton beam therapy for stage I non-small cell lung cancer: Clinical outcomes and prognostic factors","volume":"54","author":"Makita","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0205","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/1754-9485.12901","article-title":"Hypofractionated proton beam therapy for centrally located lung cancer","volume":"63","author":"Nakamura","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijrobp.2005.10.031","article-title":"High-dose proton beam therapy for Stage I non\u2013small-cell lung cancer","volume":"65","author":"Nihei","year":"2006","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0215","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1515\/raon-2017-0023","article-title":"High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer","volume":"51","author":"Ono","year":"2017","journal-title":"Radiology and Oncology"},{"key":"10.1016\/j.ctrv.2022.102464_b0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/JTO.0b013e31824de0bf","article-title":"Proton SBRT for Medically Inoperable Stage I NSCLC","volume":"7","author":"Westover","year":"2012","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0225","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ijrobp.2013.05.002","article-title":"High-Dose Hypofractionated Proton Beam Radiation Therapy Is Safe and Effective for Central and Peripheral Early-Stage Non-Small Cell Lung Cancer: Results of a 12-Year Experience at Loma Linda University Medical Center","volume":"86","author":"Bush","year":"2013","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0230","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JTO.0b013e318288ab02","article-title":"Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a\u2013T2bN0M0) Non\u2013Small-Cell Lung Cancer","volume":"8","author":"Iwata","year":"2013","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0235","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2013.03.035","article-title":"Phase 1 Study of Dose Escalation in Hypofractionated Proton Beam Therapy for Non-Small Cell Lung Cancer","volume":"86","author":"Gomez","year":"2013","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cllc.2015.11.013","article-title":"Clinical Outcomes and Prognostic Factors of High-Dose Proton Beam Therapy for Peripheral Stage I Non-Small-Cell Lung Cancer","volume":"17","author":"Hatayama","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2022.102464_b0245","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/0284186X.2020.1759821","article-title":"Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer","volume":"59","author":"Kharod","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0250","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3109\/02841869509127197","article-title":"Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patients","volume":"34","author":"Blomgren","year":"1995","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0255","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.ijrobp.2011.03.052","article-title":"Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer","volume":"81","author":"Widder","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102464_b0260","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ijrobp.2012.07.2354","article-title":"Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly","volume":"84","author":"Shirvani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102464_b0265","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3109\/0284186X.2013.813635","article-title":"Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates","volume":"52","author":"Jeppesen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0270","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2015.12.026","article-title":"A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis","volume":"118","author":"Chiang","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.radonc.2018.07.008","article-title":"Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer","volume":"129","author":"Haque","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0280","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2009.08.003","article-title":"Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis","volume":"95","author":"Grutters","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0285","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2016.08.015","article-title":"SPACE \u2013 A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC","volume":"121","author":"Nyman","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0295","doi-asserted-by":"crossref","unstructured":"Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017; 28: iv1\u2013iv21.","DOI":"10.1093\/annonc\/mdx222"},{"key":"10.1016\/j.ctrv.2022.102464_b0300","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.radonc.2008.03.007","article-title":"Can protons improve SBRT for lung lesions? Dosimetric considerations","volume":"88","author":"Georg","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0305","unstructured":"Chang JY. Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)- ClinicalTrials.gov Identifier: NCT01511081, https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01511081?term=proton+therapy&type=Intr&cond=Non+Small+Cell+Lung+Cancer&age=12&draw=2&rank=3 (accessed 31 October 2021)."},{"key":"10.1016\/j.ctrv.2022.102464_b0310","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1620\/tjem.238.339","article-title":"Dosemetric Parameters Predictive of Rib Fractures after Proton Beam Therapy for Early-Stage Lung Cancer","volume":"238","author":"Ishikawa","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.ctrv.2022.102464_b0315","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/0284186X.2012.718094","article-title":"Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma","volume":"52","author":"Kanemoto","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0320","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.prro.2017.12.007","article-title":"Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies","volume":"8","author":"Yeung","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0325","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2020.03.012","article-title":"End-of-Range Radiobiological Effect on Rib Fractures in Patients Receiving Proton Therapy for Breast Cancer","volume":"107","author":"Wang","year":"2020","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0330","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2022.102464_b0335","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jtho.2021.04.002","article-title":"Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios","volume":"16","author":"Andruska","year":"2021","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0340","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2014.11.036","article-title":"Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: Controversies, insights, and changing horizons","volume":"114","author":"Louie","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0345","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","article-title":"Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non\u2013small-cell lung cancer","volume":"65","author":"Chang","year":"2006","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0350","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.2009.24.7221","article-title":"Mature Results of an Individualized Radiation Dose Prescription Study Based on Normal Tissue Constraints in Stages I to III Non\u2013Small-Cell Lung Cancer","volume":"28","author":"van Baardwijk","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2022.102464_b0355","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2021.01.014","article-title":"Towards the clinical implementation of intensity-modulated proton therapy for thoracic indications with moderate motion: Robust optimised plan evaluation by means of patient and machine specific information","volume":"157","author":"Ribeiro","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0360","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijrobp.2009.04.028","volume":"77","author":"Zhang","year":"2010","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2022.102464_b0365","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3857\/roj.2019.00633","article-title":"Current status of proton therapy techniques for lung cancer","volume":"37","author":"Han","year":"2019","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ctrv.2022.102464_b0370","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/0284186X.2017.1371325","article-title":"Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in \u03b1\/\u03b2","volume":"56","author":"Paganetti","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0375","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non\u2013Small-Cell Lung Cancer: What We Have Learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2022.102464_b0380","doi-asserted-by":"crossref","first-page":"104c","DOI":"10.21037\/atm-21-6256","article-title":"Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ctrv.2022.102464_b0385","article-title":"Stereotactic body radiotherapy versus surgery for early-stage non-small cell lung cancer: an updated meta-analysis involving 29,511 patients included in comparative studies","volume":"48","author":"Viani","year":"2022","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.ctrv.2022.102464_b0390","unstructured":"The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. GRADE Handbook- Introduction to GRADE Handbook, https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.w6r7mtvq3mjz (accessed 31 October 2021)."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:29:11Z","timestamp":1759656551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":78,"alternative-id":["S0305737222001335"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102464","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102464"}}